The effect of pre-analytical and physiological variables on cell-free DNA fragmentation

Assays that account for the biological properties and fragmentation of cell-free DNA (cfDNA) can improve the performance of liquid biopsy. However, pre-analytic and physiological differences between individuals on fragmentomic analysis are poorly defined. We analyzed the impact of collection tube, plasma processing time and physiology on the size distribution of cfDNA, their genome-wide representation and sequence diversity at the cfDNA fragment-ends using shallow Whole Genome Sequencing. We observed that using different stabilizing collection tubes, or processing times does not affect the cfDNA fragment sizes, but can impact the genome-wide fragmentation patterns and fragment-end sequences of cfDNA. In addition, beyond differences depending on the gender, the physiological conditions tested between 63 individuals (age, body mass index, use of medication and chronic conditions) minimally influenced the outcome of fragmentomic methods. Our results highlight that fragmentomic approaches have potential for implementation in the clinic, pending clear traceability of analytical and physiological factors.

[1]  N. Rosenfeld,et al.  Fragmentation patterns and personalized sequencing of cell‐free DNA in urine and plasma of glioma patients , 2021, EMBO molecular medicine.

[2]  Nathan C. Sheffield,et al.  Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden , 2021, Nature Communications.

[3]  H. Nielsen,et al.  Age‐stratified reference intervals unlock the clinical potential of circulating cell‐free DNA as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer , 2020, International journal of cancer.

[4]  V. Wong,et al.  Detection and characterization of jagged ends of double-stranded DNA in plasma , 2020, Genome research.

[5]  F. Mouliere,et al.  Toward the Early Detection of Cancer by Decoding the Epigenetic and Environmental Fingerprints of Cell-Free DNA. , 2019, Cancer cell.

[6]  Svenn-Arne Dragly,et al.  Perineuronal nets stabilize the grid cell network , 2019, bioRxiv.

[7]  H. Nielsen,et al.  Genome-wide cell-free DNA fragmentation in patients with cancer , 2019, Nature.

[8]  Peiyong Jiang,et al.  Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin , 2019, Genome research.

[9]  Ali Rashidfarrokhi,et al.  Dnase1l3 deletion causes aberrations in length and end-motif frequencies in plasma DNA , 2018, Proceedings of the National Academy of Sciences.

[10]  C. Franceschi,et al.  Cell‐free DNA as a biomarker of aging , 2018, Aging cell.

[11]  T. V. van Leeuwen,et al.  Centrifugation affects the purity of liquid biopsy‐based tumor biomarkers , 2018, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[12]  Keval Patel,et al.  Enhanced detection of circulating tumor DNA by fragment size analysis , 2018, Science Translational Medicine.

[13]  N. Rosenfeld,et al.  Detection of cell‐free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients , 2018, EMBO molecular medicine.

[14]  N. Rosenfeld,et al.  Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients , 2018, The Journal of molecular diagnostics : JMD.

[15]  V. Wong,et al.  Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma , 2018, Proceedings of the National Academy of Sciences.

[16]  Maximilian Diehn,et al.  Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. , 2018, Archives of pathology & laboratory medicine.

[17]  Nikhil Wagle,et al.  Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors , 2017, Nature Communications.

[18]  Winnie S. Liang,et al.  Evaluation of pre-analytical factors affecting plasma DNA analysis , 2017, bioRxiv.

[19]  M. Meyer,et al.  Single-stranded DNA library preparation from highly degraded DNA using T4 DNA ligase , 2017, Nucleic acids research.

[20]  V. Velculescu,et al.  The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA , 2016, Clinical Cancer Research.

[21]  Noah C Welker,et al.  Fragment Length of Circulating Tumor DNA , 2016, PLoS genetics.

[22]  Matthew W. Snyder,et al.  Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin , 2016, Cell.

[23]  Min Seong Kim,et al.  Single-stranded DNA library preparation uncovers the origin and diversity of ultrashort cell-free DNA in plasma , 2015, Scientific Reports.

[24]  Ancha Baranova,et al.  Non-random fragmentation patterns in circulating cell-free DNA reflect epigenetic regulation , 2015, BMC Genomics.

[25]  N. Thorne,et al.  High-resolution characterization of sequence signatures due to non-random cleavage of cell-free DNA , 2015, BMC Medical Genomics.

[26]  F. Mouliere,et al.  Circulating cell free DNA: Preanalytical considerations. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[27]  M. Ychou,et al.  High Fragmentation Characterizes Tumour-Derived Circulating DNA , 2011, PloS one.

[28]  Yama W. L. Zheng,et al.  Maternal Plasma DNA Sequencing Reveals the Genome-Wide Genetic and Mutational Profile of the Fetus , 2010, Science Translational Medicine.

[29]  K. C. Chan,et al.  Effects of preanalytical factors on the molecular size of cell-free DNA in blood. , 2005, Clinical chemistry.

[30]  F. O. Fackelmayer,et al.  DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. , 2001, Cancer research.

[31]  T. Schlange,et al.  Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows. , 2019, Clinical chemistry.